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A lipotoxic placental environment is recognized in maternal obesity, with increased inﬂammation and oxidative stress. These
changes might alter mitochondrial function, with excessive production of reactive oxygen species, in a vicious cycle leading to
placental dysfunction and impaired pregnancy outcomes. Here, we hypothesize that maternal pregestational body mass index
(BMI) and glycemic levels can alter placental mitochondria. We measured mitochondrial DNA (mtDNA, real-time PCR) and
morphology (electron microscopy) in placentas of forty-seven singleton pregnancies at elective cesarean section. Thirty-seven
women were normoglycemic: twenty-one normal-weight women, NW, and sixteen obese women, OB/GDM(−). Ten obese
women had gestational diabetes mellitus, OB/GDM(+). OB/GDM(−) presented higher mtDNA levels versus NW, suggesting
increased mitochondrial biogenesis in the normoglycemic obese group. These mitochondria showed similar morphology to NW.
On the contrary, in OB/GDM(+), mtDNA was not signiﬁcantly increased versus NW. Nevertheless, mitochondria showed
morphological abnormalities, indicating impaired functionality. The metabolic response of the placenta to impairment in obese
pregnancies can possibly vary depending on several parameters, resulting in opposite strains acting when insulin resistance of
GDM occurs in the obese environment, characterized by inﬂammation and oxidative stress. Therefore, mitochondrial alterations
represent a feature of obese pregnancies with changes in placental energetics that possibly can aﬀect pregnancy outcomes.
1. Introduction
The placenta is a metabolically active organ with multiple
functions connecting the mother and the fetus for a suc-
cessful outcome of pregnancy [1].
Mitochondrial oxidative phosphorylation and substrate
oxidation represent the main energy source for placental
function [2]. Therefore, mitochondrial function or dys-
function plays an important role in metabolic health and
cellular fate [3]. In the human and rodent placenta, both
nutritional and hypoxic stresses can alter mitochondrial
function [4–10], with changes in mitochondrial biogenesis,
function, and morphology leading to placental dysfunc-
tion. Placental alterations can aﬀect fetal metabolism and
development possibly leading to higher risk of developing
disease in the future adult [11].
In the last decade, obesity has become a global problem
[12]. Maternal obesity (MO) is expanding exponentially
worldwide to almost epidemic proportions, with an addi-
tional 5–10% of pregnant women with diabetes, representing
a signiﬁcant risk factor for adverse pregnancy outcomes
[13–17] with both immediate and long-term consequences
[11, 18–22]. However, molecular mechanisms underlying
programming eﬀects have been only partially identiﬁed.
Impaired placental transfer and metabolism of energy sub-
strates in maternal obesity and/or diabetes mellitus have
been reported [23, 24]. A lipotoxic placental environment
is indeed recognized in maternal obesity, with an altered
metabolome proﬁle, increased inﬂammation and oxidative
stress, and decreased regulators of angiogenesis [25–28].
This might alter mitochondrial function, resulting in exces-
sive production of reactive oxygen species and oxidative
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stress, in a vicious cycle leading to placental dysfunction and
impaired pregnancy outcomes.
In this study, we addressed the hypothesis that maternal
pregestational body mass index (BMI) and glycemic levels
can alter placental mitochondria, by measuring mitochon-
drial content and morphology in term placentas sampled at
elective cesarean section.
2. Materials and Methods
Pregnant women were enrolled in the Unit of Obstetrics and
Gynecology of the Luigi Sacco Hospital in Milan.
The study protocol was approved by the local Institu-
tional Review Board (Luigi Sacco Hospital Ethical Com-
mittee), and all participants gave their informed consent.
2.1. Population. Only Caucasian women with singleton
spontaneous pregnancy and delivering at term by elective
cesarean section were included in this study. Cesarean sec-
tions before labor were performed for breech presentation,
repeated caesarean section, or maternal request. Exclusion
criteria were represented by maternal-fetal infections or
autoimmune diseases, maternal smoking and drug-alcohol
abuse, fetal malformations, chromosomal disorders, pre-
eclampsia, and intrauterine growth restriction.
Forty-seven pregnant women were eligible for the study.
Thirty-seven presented normal glycemia values based
on an oral glucose tolerance test (OGTT—75 g) [29].
Among them, twenty-one were within normal weight
(NW; 18.5≤BMI< 25 kg/m2) and sixteen were obese (OB/
GDM(−); BMI≥ 30 kg/m2) according to their pregestational
BMI [30].
Ten women were diagnosed with gestational diabetes
mellitus (GDM) according to the OGTT at 24–28 weeks of
gestation, and all of them were obese (OB/GDM(+)). Women
with GDM underwent daily checks of glycemia.
All women were given nutritional and lifestyle advice and
recommendations on weight gain during pregnancy follow-
ing IOM guidelines, depending on pregestational BMI [30].
Obese patients had regular speciﬁc checkups in a ded-
icated antenatal clinic, where they received speciﬁc dietary
indication to support the control of their gestational
weight gain and their glycemia levels. No patient needed
insulin therapy.
NWwomen had physiological pregnancies with a normal
intrauterine growth and appropriate for gestational age
birth weight according to reference ranges for the Italian
population [31].
2.2. Data Collection.Maternal medical history, demographic,
anthropometric, obstetric, and neonatal data were recorded
at recruitment and after cesarean delivery.
Maternal hemoglobin was measured at 34–36 weeks.
Maternal fasting glycemia was obtained from the ﬁrst value
of the OGTT performed between 24 and 28 weeks.
2.3. Sample Collection and Processing.Human placentas were
collected immediately after elective cesarean section, in the
absence of labor. Placentas were weighed after discarding
membranes and cord from the disc, and biometric measure-
ments were performed as previously described [18].
After removing the maternal decidua, placental biopsies
(~1 cm3) were sized from diﬀerent cotyledons [32] midway
between the cord insertion and placental border. Placental
villi were then washed in PBS (Dulbecco’s phosphate-
buﬀered solution; Euroclone, Milano, Italy) and immediately
frozen in liquid nitrogen to be stored at −80°C until mtDNA
analysis or alternatively were ﬁxed with 2.5% glutaraldehyde
for electron microscopy.
2.3.1. Placenta mtDNA Content. Frozen placental fragments
(90mg) were minced in a TRIzol reagent (Roche Diagnostics,
Indianapolis, IN, USA) with a Potter homogenizer. Total
DNA was isolated from this mixture with a chemical proce-
dure, following the manufacturer’s instructions. DNA
concentrations were measured by a NanoDrop ND1000
spectrophotometer (NanoDrop Technologies; Wilmington,
DE, USA).
Mitochondrial DNA (mtDNA) content was assessed by
real-time PCR, normalizing levels of a mitochondrial gene
(cytochrome-β, CYB) to those of a single-copy nuclear gene
(RNase-P) (2−ΔCq method). Brieﬂy, 30 nanograms of total
DNA was analyzed in triplicate with TaqMan assays (CYB:
Hs02596867_s1 and RNase-P: 4316844) by 7500 Fast Real-
Time PCR (Applied Biosystems, Thermo Fisher Scientiﬁc;
Carlsbad, CA, USA); Cq values with standard deviation
exceeding 0.25 were excluded.
2.3.2. Electron Microscopy. Cells were ﬁxed with 2.5% glutar-
aldehyde in 100mM cacodylate buﬀer pH7.4 for 1 hour at
room temperature. After several washes in cacodylate buﬀer,
cells were postﬁxed with 1% osmium tetroxide and 1.5%
potassium ferrocyanide in 100mM cacodylate buﬀer pH7.4
for 1 hour on ice. After a rinse in dH2O, samples were en bloc
stained in 0.5% uranyl acetate overnight and dehydrated in
increasing concentrations of ethanol and ﬁnally embedded
in Epon. Samples were cured at 60°C in an oven for 48 h.
Epon blocks were sectioned using a Leica EM UC7 ultrami-
crotome (Leica Microsystems, UK). Ultrathin sections
(70 nm) were contrasted with 2% uranyl acetate and Sato’s
lead solutions and observed with a LEO 912AB Zeiss
Transmission Electron Microscope (Carl Zeiss, Oberkochen,
Germany). Digital micrographs were taken with a 2k× 2k
bottom-mounted slow-scan ProScan camera (ProScan,
Lagerlechfeld, Germany) controlled by the EsivisionPro 3.2
software (Soft Imaging System, Münster, Germany).
2.4. Statistical Analyses. Data are presented as mean±
standard error.
Maternal, fetal, and molecular data were compared
among study groups by one-way analysis of variance
(ANOVA), having preliminarily veriﬁed that no serious
statistical violations occurred. Tukey HSD test was then run
as a post hoc test.
A two-way between-group ANOVA was conducted to
explore the impact of maternal BMI/GDM and fetal sex
(independent variables), as individual or joint eﬀect, on
placental levels of mtDNA (dependent variable).
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Chi-square analyses were performed to compare anemia
frequencies among groups, using Yates continuity correction.
Correlations describing the strength and direction of the
relationships between 2 parameters were assessed using the
Pearson product-moment correlation.
All statistical tests were 2-sided, and p values< 0.05
were considered statistically signiﬁcant. Statistical analysis
was performed using SPSS (version 24.00, IBM Statistics;
Armonk, NY, USA).
3. Results
3.1. Characteristics of the Study Population. Maternal, fetal
and placental data are reported in Table 1.
According to inclusion criteria, pregestational BMI
was signiﬁcantly diﬀerent among groups (F(2, 46) = 78.52,
p ≤ 0 001), being higher in the two obese groups compared
to NW. Obese women gained on average less weight during
pregnancy compared to normal weight, mostly remaining
within IOM recommended limits for gestational weight gain
during pregnancy of obese women [30]. As expected, mater-
nal fasting glycemia was signiﬁcantly diﬀerent among groups
(F(2, 46) = 3.71, p = 0 03), with OB/GDM(+) showing higher
levels compared to normoglycemic groups (Tukey HSD test,
p = 0 03). Hemoglobin levels were lower in the two OB
groups compared to NW, though not signiﬁcant. However,
anemia (Hb< 11.0 g/dl) frequency was higher in OB, result-
ing more than two-fold higher in OB/GDM(−) (56%) and
in OB/GDM(+) (50%) than in NW (25%) subjects.
Maternal age, gestational age, and fetal weight did not
diﬀer among groups.
There was a statistically signiﬁcant diﬀerence in placental
weight (F(2, 46) = 4.75, p = 0 01). Post hoc comparisons
using the Tukey HSD test indicated that the mean score for
OB/GDM(+) was signiﬁcantly higher compared to the NW
group (p = 0 01).
Placental eﬃciency (fetal/placental weight ratio) was sig-
niﬁcantly diﬀerent among groups (F(2, 46) = 3.29, p = 0 04),
with OB/GDM(+) showing decreased placental eﬃciency
compared to NW (p = 0 03).
In our study population, placental eﬃciency was signiﬁ-
cantly and positively correlated with maternal Hb (p =
0 005, r = 0 412, Figure 1) and with gestational age (p =
0 001, r = 0 457), while it was negatively correlated with
placental thickness (p = 0 03, r = −0 336). Maternal Hb also
positively correlated with gestational age (p = 0 004, r =
0 422) and negatively with placental weight (p = 0 03, r =
−0 323) (data not shown).
Among the analyzed pregnancies, 23 carried male fetuses
(15 of NW, 6 of OB/GDM(−), and 2 of OB/GDM(+)
mothers) and 24 carried female fetuses (6 of NW, 10 of
OB/GDM(−), and 8 of OB/GDM(+) mothers).
3.2. mtDNA Content in Placental Tissue.A one-way between-
group analysis of variance was conducted to explore the
impact of obesity and GDM on levels of mitochondrial
DNA. There was a statistically signiﬁcant diﬀerence among
groups in mtDNA levels (F(2, 46) = 3.03, p = 0 49). Post
hoc comparisons using the Tukey HSD test indicated that
the mean score for the OB/GDM(−) group was signiﬁcantly
higher compared to NW (p = 0 047), while OB/GDM(+)
was not (Figure 2).
Figure 3(a) shows the relation between mtDNA levels
and pregestational BMI in the study population. There was
a signiﬁcant correlation in patients without a diagnosis of
GDM, indicated by the regression line (p = 0 010, r = 0 419),
Table 1: Maternal, fetal and placental characteristics in the study population.
NW, n = 21 OB/GDM(−), n = 16 OB/GDM(+), n = 10
Maternal data
Age, years 35.7± 1.02 32.7± 1.26 35.7± 1.39
Pregestational BMI, kg/m2 21.5± 0.45 34.9± 1.17∗∗∗ 35.6± 1.46∗∗∗
Fasting glycemia, mg/dl 81.4± 1.72 82.0± 1.80 90.4± 4.13∗
Hb, g/dl 11.4± 0.20 10.7± 0.34 11.1± 0.27
GWG, kg 10.38± 0.58 7.94± 1.06 8.50± 1.57
GWG to IOM advised limits, % 64.9± 3.65 95.5± 9.18 92.8± 17.43
Fetal & placental data at delivery
Gestational age, weeks 39.2± 0.12 39.1± 0.07 39.1± 0.05
Fetal weight, g 3329.6± 63.1 3339.1± 87.8 3394.0± 126.0
Placental weight, g 460.6± 19.2 488.4± 22.0 559.0± 20.5∗∗
Placental eﬃciency 7.54± 0.41 7.00± 0.30 6.11± 0.23∗
Placental area, cm2 257.5± 15.7 243.7± 16.2 259.3± 17.7
Placental thickness, cm 1.84± 0.12 2.12± 0.15 2.25± 0.17
Umbilical vein Hb, g/dl 14.0± 0.34 14.4± 0.48 13.7± 0.51
Data are presented as mean ± standard error. Post hoc comparisons using the Tukey HSD test: ∗p ≤ 0 05, ∗∗p ≤ 0 01, ∗∗∗p ≤ 0 001 versus NW. NW: normal
weight; OB/GDM(−): obese without a diagnosis of GDM; OB/GDM(+): obese with GDM; GDM: gestational diabetes mellitus; BMI: body mass index;
maternal fasting glycemia: referred to the ﬁrst value of the oral glucose tolerance test (OGTT); Hb: hemoglobin; GWG: gestational weight gain;
IOM: Institute of Medicine; placental eﬃciency: fetal/placental weight ratio; placental area: (larger diameter) × (smaller diameter) × π/4 .
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while no signiﬁcant correlation was found in OB patients
with GDM. mtDNA also negatively correlated with maternal
Hb (p = 0 011, r = −0 373) (Figure 3(b)) and umbilical vein
Hb (p = 0 019, r = −0 406) (Figure 3(c)).
There were no diﬀerences in mtDNA levels depending on
fetal sex. The two-way between-group analysis of variance
showed that the interaction eﬀect between fetal sex and
maternal pregestational BMI was not statistically signiﬁcant
(F(2, 46) = 0.61, p = 0 94) (data not shown).
3.3. Electron Microscopic Analysis of Syncytiotrophoblast. The
mitochondrial proﬁles in the syncytiotrophoblast of both
NW and OB/GDM(−) placentas were round or elongated
with a very dense matrix and similar structure of the cristae
(Figures 4(a) and 4(b)). In contrast, syncytiotrophoblast
mitochondria in OB/GDM(+) placentas displayed morpho-
logical abnormalities, showing a matrix with very low density
and vesicle-like or disrupted cristae, forming an irregular pat-
tern (Figure 4(c)).
4. Discussion
Recently, maternal obesity has been associated with a lipo-
toxic placental environment, with increased placental lipids,
inﬂammation, and oxidative stress, together with a less eﬃ-
cient fetal/placental ratio and altered metabolome proﬁle
[18, 23, 25, 27]. The cellular stress characterizing this mater-
nal environment may adversely aﬀect placental development
and function possibly altering fetal growth and development.
Indeed, oxidative stress is one of the hallmark responses to
intracellular lipid overload. High levels of free fatty acids
impact the mitochondrial (mt) membrane structure, causing
the release of reactive oxygen species (ROS) that can react
with macromolecules and damage intracellular membranes
and DNA [33]. These alterations can in turn aﬀect mito-
chondrial structure and function, in a vicious cycle of
mitochondrial abnormalities and ROS formation, possibly
representing a key mechanism of placental dysfunction in
a disease condition.
Several animal models of MO report mt dysfunctions in
pancreatic islets, liver, or skeletal muscle of the oﬀspring
[34, 35]. However, maternal obesity and diabetes are not
always associated with obvious fetal distress, and the possible
placental adaptation may explain it [24].
In this study, we addressed the hypothesis that placental
mitochondria in pregnancy can be altered by elevated
maternal BMI and/or by metabolic alterations occurring in
gestational diabetes mellitus.
We studied placentas at term only delivered by elective
cesarean section, in order to avoid possible alterations of
mitochondrial content or function due to labor [36]. Obese
patients were followed during pregnancy with a speciﬁc
counseling including nutritional and lifestyle advices. This
resulted in lower gestational weight gain compared to nor-
mal weight patients, as recommended by IOM guidelines
[30]. Our study population was also carefully selected by
excluding women carrying further conditions possibly
aﬀecting mitochondrial characteristics, such as maternal
smoking or drug-alcohol abuse and maternal or fetal
pathologies. Obese women with GDM were included, in
order to evaluate the additional eﬀect of increased glycemia
to placental mitochondrial features.
4.1. mtDNA in Obese Pregnancies without GDM. mtDNA
levels are largely recognized as a measure of the mitochon-
drial content [4, 37, 38]. We found higher levels of mtDNA,
accounting for the increased mitochondrial content in pla-
cental cells of women with an obese pregestational BMI with-
out a diagnosis of GDM (Figure 2). The morphology of
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Figure 1: Signiﬁcant correlation between placental eﬃciency and
maternal hemoglobin (p = 0 005, r = 0 412). NW: normal-weight
women; OB/GDM(−): obese women without a diagnosis of GDM;
OB/GDM(+): obese women with GDM.
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Figure 2: Placental mtDNA levels. ∗p = 0 047 versus NW, Tukey
HSD test. NW: normal-weight women; OB/GDM(−): obese
women without a diagnosis of GDM; OB/GDM(+): obese women
with GDM.
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mitochondria in the syncytiotrophoblast of the OB/GDM(−)
group was overall similar to the NW group, suggesting no
alterations in mitochondrial function (Figures 4(a) and
4(b)). A compensatory increase in mitochondrial biogenesis
can be explained by the endocrine stimuli due to high intra-
cellular fatty acid levels and oxidative stress occurring in the
lipotoxic environment of obese placentas [9, 34]. Indeed,
altered levels of mtDNA as well as the impairment of nutrient
transport systems have been reported in previous studies in
the placental tissue of diﬀerent pregnancy pathologies
characterized by elevated oxidative stress and inﬂammation
levels, such as intrauterine growth restriction and preeclamp-
sia [4, 5, 39–43]. The positive correlation between placental
mtDNA and maternal BMI that was observed in this study
supports this hypothesis (Figure 3(a)).
Diﬀerently from our study, decreased mtDNA copy
number has been previously reported in placentas of obese
compared to not-obese women [9, 44]. However, diﬀerent
gene assays and diﬀerent population criteria were employed
in these studies. One of the strengths of the present study is
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Figure 3: (a) Correlation between placental mtDNA and maternal pregestational BMI. The correlation is signiﬁcant in patients without a
diagnosis of GDM, indicated by the regression line (p = 0 010, r = 0 419). (b). Correlation between placental mtDNA and maternal
hemoglobin (p = 0 011, r = −0 373). (c). Correlation between placental mtDNA and umbilical vein hemoglobin (p = 0 019, r = −0 406).
NW: normal-weight women; OB/GDM(−): obese women without a diagnosis of GDM; OB/GDM(+): obese women with GDM.
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the careful selection of a very well characterized population
of uncomplicated pregnancies. We excluded any maternal
or fetal infection or autoimmune disease, maternal smoking
or drug-alcohol abuse, fetal malformations, chromosomal
disorders, preeclampsia, and intrauterine growth restriction,
all of which can aﬀect mitochondrial biogenesis and func-
tionality. Moreover, only Caucasian women were selected,
as diﬀerent mitochondrial DNA haplogroups have been
identiﬁed and have been suggested to possibly contribute to
the genetic component of complex disorders [45–47]. Finally,
all women included in this study were counseled with
nutritional and lifestyle advice and recommendations on
weight gain during pregnancy, and obese patients had
regular speciﬁc checkups in a dedicated antenatal clinic
with speciﬁc dietary indication.
Interestingly, in a recent review on mitochondrial fea-
tures in gestational disorders, Holland and colleagues
reported that mitochondrial content has been found to be
increased or decreased in the same pregnancy pathology by
diﬀerent studies [48]. These apparent diﬀerences within the
same pathologies can be explained by the diﬀerent severity
or timing of the insult and the resulting capacity of the tissue
to respond. Indeed, although in several diseases, mitochon-
drial biogenesis is thought to occur as a compensatory mech-
anism to the cell distress [4, 49–52], on the other hand, the
increase of mitochondrial ROS production could damage
the mitochondrial DNA and membranes, thus inhibiting
the adaptive mitochondrial increase.
Therefore, the diﬀerent inclusion/exclusion criteria of
the studied population, together with diﬀerent clinical pro-
tocols in nutritional and lifestyle advice, can lead to diﬀerent
results regarding the mitochondrial responses. This is also
suggested in the recent study reporting increased placental
mitochondrial content in early-onset but not late-onset
preeclampsia [41].
4.2. mtDNA in Obese Pregnancies with GDM. When analyz-
ing placentas of obese women with GDM, we did not ﬁnd a
signiﬁcant increase in mtDNA levels (Figure 2). However,
placentas of OB/GDM(+) women showed dysfunctional
syncytiotrophoblast mitochondria, with morphological
abnormalities. In particular, electron microscopy revealed a
loss of matrix density and disorganization of inner mem-
brane cristae (Figure 4(c)). Interestingly, also animal models
of diabetes showed a reduced number of mitochondria, with
abnormal morphology, associated to mitochondrial dysfunc-
tion [53]. Notably, large lipid droplets that stock lipids as
energy-rich storage compounds were observed. In this
context, lipid droplets may support feeble mitochondrial
function by supplying fatty acids for mitochondrial β oxida-
tion and protect mitochondria from lipotoxicity [54].
Our results therefore suggest that placental mitochondria
of obese women with GDM do not show signiﬁcant
alterations in biogenesis but present altered morphology,
indicating an impairment of their function.
The OB/GDM(+) group also presented decreased placen-
tal eﬃciency compared to NW. Indeed, GDM has been
associated with impaired placental development showing
villous immaturity or alterations in villous branching, as well
as impaired placental angiogenesis, villous vasculature, and
uteroplacental perfusion [55–57]. Oxidative stress markers
have also been reported in GDM placentas [58], possibly
aﬀecting the physiology of the placental vasculature and
mitochondrial morphology.
Insulin resistance and altered metabolic proﬁles charac-
terize the diabetic condition. Insulin resistance has been cor-
related in several tissues with a decrease in mitochondrial
function and mitochondrial DNA copy number, a reduction
in mitochondrial fusion and increase in their ﬁssion and with
alterations of mitochondrial size and density. The possible
role of epigenetic regulation is emerging for these alterations
[59–64]. Indeed, some authors recently hypothesized that
insulin resistance acts on the expression of proteins involved
in the methylation machinery of both nuclear and mito-
chondrial DNA, aﬀecting the expression of genes involved
in mtDNA replication, thus leading to decreased mitochon-
drial biogenesis [62, 65, 66]. However, other studies report
either no impairment or a compensatory increase of mito-
chondrial function and oxidative capacity in conditions of
insulin resistance [67, 68]. Hence, the relationship between
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Figure 4: Electron microscopy of term placenta villi showing representative sections of syncytiotrophobast cells from NW (a), OB/GDM(−)
(b), and OB/GDM(+) (c) term placentas. M: mitochondria; ER: endoplasmic reticulum; LD: lipid droplet. NW: normal-weight women; OB/
GDM(−): obese women without a diagnosis of GDM; OB/GDM(+): obese women with GDM.
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mitochondria and insulin action is highly complex and there
is still much to learn in this area [3].
Similarly to our results, decreased levels of placental
mtDNA have been recently reported in diabetic pregnancies
[69], together with lower mitochondrial respiratory chain
enzyme activities [9]. In our population, diﬀerent levels of
placental mtDNA in obese with or without GDM may be
the result of opposite strains. Maternal diabetes has been
associated with a decrease of placental mitochondrial levels
[9, 69], while the obese environment associated with inﬂam-
mation and oxidative stress tends to promote a compensa-
tory mitochondrial biogenesis. In the recent study, we
reported comparable results in the maternal blood of obese
women with or without GDM [52]. Levels of mtDNA in
maternal blood may indeed result by the release of placental
cell debris in the maternal circulation [70].
In addition, complex changes in the metabolic proﬁle
have been shown in obese pregnant women with or without
GDM [25, 71]. White et al. recently showed that in addition
to the dysregulation of glucose metabolism, GDM obese
women compared with non-GDM obese women exhibited
exaggerated dyslipidemic proﬁles prior to the GDM diagno-
sis, at week 17, when placentation still occurs. This possibly
reﬂects enhanced insulin resistance in peripheral tissues
of GDM women and a consequent reduced suppression
of lipolysis, aﬀecting lipid metabolism pathways. Increased
insulin resistance and higher levels of lipids and lipopro-
teins have also been shown at mid and late pregnancy in
women with GDM compared to normal glucose tolerant
patients [72].
Moreover, GDM-obese women showed metabolic pat-
terns consistent with perturbed energy pathways [25, 71].
Particularly, obese women with GDM showed increased
levels of acetoacetate (likely secondary to unregulated fatty
acid oxidation in mitochondria) and citrate (an early
intermediate of the tricarboxylic acid cycle, occurring in
mitochondria). These evidences suggest a speciﬁc metabolic
milieu of GDM compared to non-GDM obese pregnant
women, which can diﬀerently aﬀect the mitochondrial func-
tion in placenta.
4.3. Relation betweenmtDNA andMaternal/Fetal Hemoglobin.
Noteworthy, in our study population, we found a signiﬁ-
cant negative correlation between placental mtDNA and
hemoglobin levels in the maternal and fetal blood
(Figures 3(b) and 3(c)). Maternal Hb also signiﬁcantly
correlated with placental eﬃciency.
Maternal systemic hemoglobin may account for maternal
nutritional status. Obese women in this study did not present
signiﬁcantly lower levels of maternal Hb, possibly due to the
speciﬁc and regular nutritional counseling given to them
during pregnancy. However, in our population anemia fre-
quency (Hb< 11.0 g/dl) was higher in both OB subgroups
compared to NW. Indeed, obesity induces a chronic, low-
grade inﬂammation with overexpression of C-reactive pro-
tein and hepcidin [26, 52] that is negatively correlated with
both maternal and cord blood iron status [73]. On the
other hand, low maternal Hb may be an index of altered
vascular oxygenation that can induce mitochondrial
biogenesis, according to the negative correlation we found
in our study population.
4.4. Limitations. A sexual dimorphism has been reported
in several placental responses to adverse environments
[13, 18, 74]. Nevertheless, in our study population, we
did not ﬁnd any interaction eﬀect between the fetal sex and
maternal pregestational BMI, suggesting that the BMI inﬂu-
ence on mtDNA levels and morphology does not depend
on fetal sex. However, a limited number of cases within each
subgroup might lead to these results. Therefore, further
investigations are needed to explore the possible eﬀect of fetal
sex on the mitochondrial content and function in placentas
of obese pregnancies with or without GDM.
Although our results on placental mitochondria of
OB/GDM(+) pregnancies comply with previous ﬁndings,
showing lower mitochondrial copy number compared to
NW placentas [9, 69], inclusion criteria of the populations
analyzed in these studies were diﬀerent to ours, also
including type 1 and type 2 diabetes mellitus, placentas
from vaginal deliveries, and diﬀerent ethnic groups, thus
keeping open the need of further studies investigating the
consequences of insulin action on placental mitochondria
in GDM pregnancies.
Moreover, whether alterations in mtDNA content of OB
placental whole tissue are due to alterations in one or more
placental cell types still remains to be investigated.
5. Conclusions
The placenta integrates nutritional and endocrine signals and
arranges its metabolic phenotype to support pregnancy. The
metabolic response of the placenta to impairment depends
on the nature, severity, and duration of the environmental
adversity [1], and in obese pregnancies, these can possibly
vary depending on several parameters like maternal glycemia
or the maternal nutritional status and lifestyle. However,
mitochondrial alterations are a clear feature of obese preg-
nancies with changes in placental energetics and consump-
tion of oxidative substrates that possibly can aﬀect fetal
delivery of nutrients and O2 with short- and long-term
consequences on the newborn.
Understanding the diﬀerences in placental metabolic
adaptation to obesity and insulin resistance might open
new perspectives for therapeutic future developments [24].
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